<DOC>
	<DOCNO>NCT01576523</DOCNO>
	<brief_summary>The aim study assess happen C1-esterase inhibitor administer skin subject hereditary angioedema . Three different dose regimen C1-esterase inhibitor assess . Each subject assign receive 2 3 dosing regimen , 4 week . The activity concentration C1-esterase inhibitor blood measure 4-week period . The study also examine well C1-esterase inhibitor administer skin tolerate subject .</brief_summary>
	<brief_title>A Study Evaluate Clinical Pharmacology Safety C1-esterase Inhibitor Administered Subcutaneous Route</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Hereditary Angioedema Types I II</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Males female age 18 year old . Laboratoryconfirmed hereditary angioedema type I II . Less two hereditary angioedema attack per month last three month . Body weight 50.0 kg 110.0 kg . Receiving prophylactic C1esterase inhibitor therapy . Received C1esterase inhibitor , ecallantide , icatibant blood product prevention treatment hereditary angioedema within 7 day screen visit . Intends use recombinant C1esterase inhibitor fresh frozen plasma acute treatment hereditary angioedema study . Received androgen therapy ( e.g. , danazol , oxandrolone , stanozolol , testosterone ) within 30 day screen visit . Female subject start take change dose hormonal contraceptive regimen hormone replacement therapy ( i.e. , estrogen/progesteronecontaining product ) within 3 month prior screen visit . Known suspected hypersensitivity study product , excipients study product . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>